Показано 0 из 0
Дата |
---|
30.11.2023 |
29.11.2023 |
28.11.2023 |
18.10.2023 |
20.09.2023 |
06.09.2023 |
05.09.2023 |
18.07.2023 |
05.07.2023 |
28.06.2023 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
|
|
|
268.50
|
268.50
|
268.50
|
|
|
9 129.00
|
|
|
|
|
268.50
|
268.50
|
268.50
|
|
|
8 592.00
|
|
|
|
|
|
|
268.50
|
|
|
554.00
|
|
|
|
|
|
|
268.50
|
|
|
805.50
|
|
|
|
|
268.50
|
268.50
|
268.50
|
|
|
6 712.50
|
|
|
|
|
|
|
330.00
|
|
|
268.21
|
|
|
|
|
|
|
330.00
|
|
|
820.29
|
|
|
|
|
|
|
330.00
|
|
|
1 181 651.00
|
|
|
|
|
330.00
|
330.00
|
330.00
|
|
|
6 600.00
|
|
|
|
|
|
|
329.35
|
|
|
329.35
|
|
ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology.